Literature DB >> 20032127

Lapatinib and metronomic capecitabine combination in an HER2-positive inflammatory breast cancer patient: a case report.

E Montagna, G Cancello, R Torrisi, S Rizzo, E Scarano, M Colleoni.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 20032127     DOI： 10.1093/annonc/mdp563

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  3 in total

Review 1.  The toxicity of anti-VEGF agents when coupled with standard chemotherapeutics.

Authors:  Jennifer A Afranie-Sakyi; Giannoula Lakka Klement
Journal:  Cancer Lett       Date:  2014-10-29       Impact factor: 8.679

2.  NDRG2 regulates adherens junction integrity to restrict colitis and tumourigenesis.

Authors:  Mengying Wei; Yongzheng Ma; Liangliang Shen; Yuqiao Xu; Lijun Liu; Xin Bu; Zhihao Guo; Hongyan Qin; Zengshan Li; Zhe Wang; Kaichun Wu; Libo Yao; Jipeng Li; Jian Zhang
Journal:  EBioMedicine       Date:  2020-10-21       Impact factor: 8.143

3.  Early relapse of inflammatory breast carcinoma treated with lapatinib and capecitabine: Ten years of complete response.

Authors:  Roberto Martin Huertas; María Fernández Abad; Elena Corral de la Fuente; Juan José Serrano Domingo; Noelia Martínez Jáñez
Journal:  Breast J       Date:  2019-09-29       Impact factor: 2.431
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.